Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit

INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Tempia Valenta, Silvia, Stecchi, Michele, Perazza, Federica, Nuccitelli, Chiara, Villanova, Nicola, Pironi, Loris, Atti, Anna Rita, Petroni, Maria Letizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/
https://www.ncbi.nlm.nih.gov/pubmed/38015342
http://dx.doi.org/10.1007/s40519-023-01625-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/
https://www.ncbi.nlm.nih.gov/pubmed/38015342
http://dx.doi.org/10.1007/s40519-023-01625-5

Ejemplares similares